NASDAQ:ANCN Anchiano Therapeutics (ANCN) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free ANCN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.95▼$1.1050-Day Range$2.82▼$59.0052-Week Range$0.51▼$10.55Volume132,623 shsAverage Volume3.15 million shsMarket Capitalization$7.57 millionP/E Ratio6.80Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Anchiano Therapeutics alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Anchiano Therapeutics Stock (NASDAQ:ANCN)Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Read More Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. ANCN Stock News HeadlinesMay 29, 2023 | finance.yahoo.comRakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture FinancingMay 27, 2023 | morningstar.comITeos Therapeutics Inc Ordinary SharesMay 20, 2023 | seekingalpha.comENDV Endonovo Therapeutics, Inc.May 18, 2023 | msn.comLooking Into Oncternal Therapeutics's Return On Capital EmployedMay 18, 2023 | msn.comAnticompetitive Behavior At United Therapeutics, Regeneron, And The FTCMay 16, 2023 | msn.comFTC sues to block Amgen’s acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comFTC sues to block Amgen acquisition of Horizon TherapeuticsMay 12, 2023 | msn.comRecap: Abeona Therapeutics Q1 EarningsMay 9, 2023 | msn.comTScan Therapeutics More than Doubles Following Deal with AmgenApril 26, 2023 | benzinga.comMersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual MeetingApril 5, 2023 | finanznachrichten.dePerspective Therapeutics, Inc.: Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of BrachytherapyMarch 27, 2023 | news.yahoo.comCigna's PBM, two others sued in Ohio over drug price fixing - WSJFebruary 25, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine PlatformFebruary 18, 2023 | benzinga.comVoyager Therapeutics Stock (NASDAQ:VYGR), Quotes and News SummaryFebruary 11, 2023 | yahoo.comMolina Healthcare, Inc. (NYSE:MOH) Q4 2022 Earnings Call TranscriptFebruary 10, 2023 | benzinga.comRevance Therapeutics Stock (NASDAQ:RVNC), Quotes and News SummaryJanuary 5, 2023 | markets.businessinsider.comJnana Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 29, 2022 | msn.comDown -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a TurnaroundDecember 27, 2022 | benzinga.comOnconova Therapeutics's Return On Capital Employed InsightsDecember 13, 2022 | barrons.com3 Reasons Amgen Is Buying Horizon — and Why It Wasn’t the Only Company InterestedDecember 13, 2022 | msn.comAmgen to buy Horizon Therapeutics in $26.4 billion dealDecember 12, 2022 | msn.comHere's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022December 12, 2022 | markets.businessinsider.comRule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plcDecember 12, 2022 | msn.comAmgen secures $28.3 billion deal to buy Horizon TherapeuticsDecember 12, 2022 | msn.comAmgen to Buy Horizon Therapeutics in $27.8 Billion DealSee More Headlines Receive ANCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2019Today6/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ANCN CUSIPN/A CIKN/A Webwww.anchiano.com Phone857-259-4622FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E Ratio6.80 Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity36.08% Return on Assets27.40% Debt Debt-to-Equity RatioN/A Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.51Miscellaneous Outstanding Shares7,420,000Free FloatN/AMarket Cap$7.57 million OptionableNot Optionable Beta0.93 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Ronald K. Knickerbocker (Age 55)Sr. VP of Clinical Devel. & Data Sciences Comp: $352kMr. Neil H. Cohen (Age 58)CEO & Director Prof. Abraham Hochberg (Age 83)Co-Founder & Chief Scientific Officer Mr. Andrew Fine (Age 51)Chief Financial Officer Mr. Avraham Hampel M.B.A.Deputy CFO & Company Sec.Mr. Or Dolev (Age 43)Controller More ExecutivesKey CompetitorsFortress BiotechNASDAQ:FBIOCara TherapeuticsNASDAQ:CARAVYNE TherapeuticsNASDAQ:VYNEMarker TherapeuticsNASDAQ:MRKRProMIS NeurosciencesNASDAQ:PMNView All Competitors ANCN Stock Analysis - Frequently Asked Questions How were Anchiano Therapeutics' earnings last quarter? Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.12. What other stocks do shareholders of Anchiano Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB). When did Anchiano Therapeutics IPO? Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. This page (NASDAQ:ANCN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
